Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Relapsed DLBCL and PT/NKCLs
NCT02597387Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), natural killer cell lymphoma (NKCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)natural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT02597387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597387.